Overexpression of long noncoding RNA NORAD in colorectal cancer associates with tumor progression.
Overexpression of long noncoding RNA NORAD in colorectal cancer associates with tumor progression.
复制标题
长链非编码RNA NORAD在结直肠癌中的过度表达与肿瘤进展相关
DOI：
10.2147/ott.s176354
复制
发表时间：
2018
影响因子：
4
通讯作者：
Wang C
中科院分区：
文献类型：
--
作者：
Wang L;Du L;Duan W;Yan S;Xie Y;Wang C
本研究的目的是阐明DNA损伤激活的长链非编码RNA（NORAD）在结直肠癌（CRC）中的作用和临床意义。对60对来自CRC患者的肿瘤和邻近非肿瘤组织进行定量实时聚合酶链反应，以确定NORAD的表达水平。NORAD表达的血清水平也在CRC患者以及良性疾病患者和健康对照的独立队列中测量。比较分析结直肠癌组织中NORAD水平与临床病理特征的关系。应用受试者工作特征曲线（ROC曲线）分析NORAD对结直肠癌的诊断价值。此外，NORAD在CRC发展中的潜在功能在体外进行了探索，使用HCT 116和SW 1116 CRC细胞系。NORAD在结直肠癌患者癌组织中的表达显著高于癌旁组织（P<0.001）。NORAD的高表达与晚期CRC相关。此外，血清水平支持NORAD可以区分CRC患者与健康对照和良性疾病患者，表明在CRC中的潜在诊断作用。ROC曲线分析显示诊断有效性，曲线下面积为0.800（95%CI：0.737-0.853）。机制研究表明，NORAD沉默减少CRC细胞增殖，迁移和侵袭。NORAD可能作为一种新的预测CRC，并可能是未来治疗的潜在目标。
The aim of this study was to elucidate the role and clinical significance of long noncoding RNA-activated by DNA damage (NORAD) in colorectal cancer (CRC). Sixty pairs of tumorous and adjacent nontumorous tissues derived from CRC patients were subjected to quantitative real-time polymerase chain reaction to determine the expression level of NORAD. The serum levels of NORAD expression were also measured in an independent cohort of CRC patients as well as patients with benign diseases and healthy controls. Comparative analyses were performed to investigate the relationships between NORAD levels in tissues and clinicopathological features of CRC. Receiver operating characteristic (ROC) curve analysis was used to assess the diagnostic value of NORAD in patients with CRC. Furthermore, the potential functions of NORAD in the development of CRC were explored in vitro, using the HCT116 and SW1116 CRC cell lines. NORAD expression was significantly upregulated in the tumorous tissues of CRC patients (P<0.001) compared to the adjacent nontumorous tissues. Higher NORAD expression was associated with advanced CRC. Moreover, serum levels supported that NORAD could distinguish CRC patients from healthy controls and patients with benign diseases, indicating a potential diagnostic role in CRC. The ROC curve analysis showed a diagnostic efficacy with area under the curve of 0.800 (95% CI: 0.737–0.853). Mechanistic investigations indicated that NORAD silencing reduced CRC cell proliferation, migration, and invasion. NORAD may serve as a novel predictor in CRC and may be a potential target for future therapy.